By Sy Mukherjee
May 14, 2019

Good afternoon, readers.

Zebra Medical Vision, an Israel-base digital health company (whose co-founder and CEO Eyal Gura was featured at our Brainstorm Health conference in San Diego last month), has won Food and Drug Administration (FDA) clearance for an A.I.-powered platform that can help detect early signs of a collapsed lung.

As far as artificial intelligence use goes—and, by that, I mean actual, practical, result-driving use of artificial intelligence—radiology has been on of the most promising sectors. Companies have been able to harness machines to scour through troves of medical imaging data to pick up on certain warning signals. It’s a similar case for Zebra Medical’s HealthPNX product, which can suss out the early indications of a pneumothorax and alert physicians to the matter.

“We are happy to add this important capability to our All-in-One (AI1) package and add more value to busy radiology departments,” said chief executive Gura in a statement.

The company’s strategy also meshes with an increasingly accepted thesis in digital medicine: The tools may be most effective when they serve as secondary helpers to a human counterpart, rather than a standalone unit.

Read on for the day’s news.

Sy Mukherjee
@the_sy_guy
sayak.mukherjee@fortune.com

SPONSORED FINANCIAL CONTENT

You May Like